AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro - BioSpace

AstraZeneca is investing up to $1.5 billion in an AI partnership to develop new treatments for metabolic and heart diseases. This matters because it could lead to new medicines, though the immediate impact depends on research success over many years.